Drug-Induced Lupus Erythematosus

被引:0
|
作者
Totri, Christine R. [1 ]
Jacob, Sharon E. [2 ]
机构
[1] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[2] Loma Linda Univ, Med Ctr, Dept Dermatol, Loma Linda, CA 92350 USA
关键词
Drug-Induced Lupus Erythematosus; Drug Reactions; Subacute Lupus Erythematosus; Systemic Lupus Erythematosus;
D O I
10.1097/JDN.0000000000000143
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Drug-induced lupus erythematosus is an autoimmune disorder, much like idiopathic systemic lupus erythematosus. As in idiopathic systemic lupus erythematosus, there is antibody generation and "accidental'' attack on normal healthy tissues in drug-induced lupus erythematosus. Symptoms and signs often resolve upon discontinuation of the offending drug, making it an important diagnosis for healthcare providers to make. An increasingly large number of medications have been linked to drug-induced lupus erythematosus. Hydralazine, isoniazid, and procainamide are the most common medications known to cause drug-induced systemic lupus, whereas hydrochlorthiazide, diltiazem (and other calcium channel blockers), and terbinafine are the most common causative agents in drug-induced subacute cutaneous lupus erythematosus.
引用
收藏
页码:237 / 239
页数:3
相关论文
共 50 条
  • [21] Drug-induced subacute cutaneous lupus erythematosus initially diagnosed as erythema annulare centrifugum
    Koztowska, Arletta
    Obtutowicz, Aleksander
    Pizun, Aleksandra
    Radzimowska-Dudek, Joanna
    Staron, Agata
    Dyduch, Grzegorz
    Obtutowicz, Bartosz
    Wojas-Pelc, Anna
    PRZEGLAD DERMATOLOGICZNY, 2024, 111 (01): : 52 - 58
  • [22] DRUG-INDUCED SYSTEMIC LUPUS-ERYTHEMATOSUS IN A 9-YEAR-OLD BOY
    ANSELL, BM
    LUPUS, 1993, 2 (03) : 193 - 194
  • [23] Drug-induced lupus: an update on its dermatologic aspects
    Marzano, A. V.
    Vezzoli, P.
    Crosti, C.
    LUPUS, 2009, 18 (11) : 935 - 940
  • [24] Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus
    Rubin, RL
    Teodorescu, M
    Beutner, EH
    Plunkett, RW
    LUPUS, 2004, 13 (04) : 249 - 256
  • [25] FAMILIAL PRIMARY GENERALIZED EPILEPSY AND DRUG-INDUCED SYSTEMIC LUPUS-ERYTHEMATOSUS - A FAMILY STUDY
    QUIETZSCH, J
    BAUMGARTEN, C
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 1992, 51 (02): : 65 - 77
  • [26] Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?
    Raschi, Emanuel
    Antonazzo, Ippazio Cosimo
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07)
  • [27] Cutaneous drug-induced lupus erythematosus: Clinical and immunological characteristics and update on new associated drugs
    Bataille, P.
    Chasset, F.
    Monfort, J. -B.
    De Risi-Pugliese, T.
    Soria, A.
    Frances, C.
    Barbaud, A.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2021, 148 (04): : 211 - 220
  • [28] A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus
    Lomicova, I.
    Suchy, D.
    Pizinger, K.
    Cetkovska, P.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (03) : 363 - 366
  • [29] Drug-Induced Lupus ErythematosusIncidence, Management and Prevention
    Christopher Chang
    M. Eric Gershwin
    Drug Safety, 2011, 34 : 357 - 374
  • [30] Two cases of late-onset drug-induced lupus erythematosus caused by ticlopidine in elderly men
    Yokoyama, Tomoko
    Usui, Takashi
    Kiyama, Kazuhiro
    Nakashima, Ran
    Yukawa, Naoichiro
    Kawabata, Daisuke
    Nojima, Takaki
    Ohmura, Koichiro
    Fujii, Takao
    Mimori, Tsuneyo
    MODERN RHEUMATOLOGY, 2010, 20 (04) : 405 - 409